RELMADA THERAPEUTICS, INC. — Director's Dealing 2021

Feb 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-02-16

Reporting Person: Kelly Paul Edward (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-16	Common Stock	M	5000	$6.00	Acquired	167295	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-16	Warrants	$6.00	M	5000	Disposed	2024-10-04	Common Stock (5000)	Direct

Footnotes

F1: This Warrant was previously reported as covering 100,000 shares of common stock at an exercise price of $1.50 per share, but was adjusted to reflect the stock split that occurred on September 30, 2019.